Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

3期 进行中（已停止招募） NCT03425643

摘要

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS).

Event Free Survival (EFS)

Up to approximately 5 years · Months

Overall Survival (OS)

Up to approximately 5 years · Months

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
• Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
• Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
• Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
• A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC

全部试验